(NYSE: CRL) Charles River Laboratories International's forecast annual revenue growth rate of 0.5% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.85%.
Charles River Laboratories International's revenue in 2025 is $4,022,597,000.On average, 6 Wall Street analysts forecast CRL's revenue for 2025 to be $191,119,304,113, with the lowest CRL revenue forecast at $190,582,322,034, and the highest CRL revenue forecast at $192,573,865,924. On average, 6 Wall Street analysts forecast CRL's revenue for 2026 to be $197,360,142,943, with the lowest CRL revenue forecast at $190,743,028,643, and the highest CRL revenue forecast at $200,672,064,518.
In 2027, CRL is forecast to generate $210,739,262,891 in revenue, with the lowest revenue forecast at $209,985,385,828 and the highest revenue forecast at $212,830,118,751.